<DOC>
	<DOCNO>NCT02640482</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ABT-493/ABT-530 adult genotype 2 chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ABT-493/ABT-530 Adults With Chronic Hepatitis C Virus ( HCV ) Genotype 2 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Screening laboratory result indicate hepatitis C virus ( HCV ) Genotype2 ( GT2 ) infection . Chronic HCV infection . Subject must HCV treatmentna√Øve fail previous HCV treatment . Subject must noncirrhotic . History severe , lifethreatening significant sensitivity excipient study drug . Female pregnant , plan become pregnant study , breastfeed ; male whose partner pregnant planning become pregnant study . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator . Positive test result Screening hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) . HCV genotype perform screen indicate coinfection 1 HCV genotype .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Treatment-Naive</keyword>
	<keyword>Hepatitis C Virus Genotype 2</keyword>
	<keyword>Sofosbuvir ( SOF ) -Experienced</keyword>
	<keyword>Treatment-Experienced</keyword>
	<keyword>Non-cirrhotic</keyword>
</DOC>